Cannabis Law Report

MARCH 17, 2022

LAKELAND, Fla. , March 17, 2022 /PRNewswire/ — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., Metrc will implement its robust track-and-trace platform to help facilitate the Minnesota Medical Cannabis Program’s data collection and regulatory oversight.

Data 52

Data Compliance Compliance Programs 52

Cannabis Law Report

AUGUST 16, 2022

16, 2022 (GLOBE NEWSWIRE) — Metrc , the most trusted and experienced provider of cannabis regulatory systems in the U.S., This marks Metrc’s 23 rd government contract to date and sixth so far in 2022. The State plans to begin accepting licensing applications for businesses on September 1, 2022. “We LAKELAND, Fla.,

Seed-To-Sale 52

Seed-To-Sale Supply Chain Data Patients 52

Cannabis Law Report

MARCH 17, 2022

Deadline to apply: March 18, 2022 by 5:00 p.m. Deadline to apply: March 31, 2022 by 5:00 p.m. Data Manager. Deadline to apply: March 31, 2022 by 5:00 p.m. Request for Qualifications (RFQ): Multimedia Profiles of Social Equity Program Participants and Supporters. Quote/bid response deadline: March 24, 2022 by 5 p.m.

Compliance 52

Compliance Compliance Research and Development Data 52

Cannabis Law Report

JANUARY 12, 2022

Through the partnership, Maya’s Real World Evidence Platform will be one of the core services offered to the association’s members when it officially launches in Q4 of 2022. We don’t believe safety and access are opposing polarities that must be constantly balanced.

Research and Development 52

Research and Development Therapy Safety Clinical Trials 52

Cannabis Law Report

AUGUST 16, 2022

August 16, 2022. To be eligible to apply for a conditional adult-use processor license, a processor must: Have applied for a cannabinoid hemp processor license before January 1, 2022; Hold an active cannabinoid hemp processor license issued by the OCM; and. The application window opened on June 28, 2022 and closes on August 31, 2022.

Supply Chain 52

Supply Chain Conditions Cannabinoids Programs 52

Cannabis Law Report

OCTOBER 22, 2021

To date, more than 50 novel compounds have been evaluated through collaborations with experienced contract research organizations for pharmacokinetic/pharmacodynamic profile, metabolic stability, receptor binding, and safety in order to identify preferred candidates for further development.

Research and Development 52

Research and Development Safety Media Data 52

Cannabis Law Report

DECEMBER 26, 2021

In furtherance of its program, the Company filed US Provisional Patent Application No. “Entheon is proud to be making significant strides in its Entheon IQ™ program,” says Timothy Ko, Chief Executive Officer of Entheon. US Provisional Patent Filed. ” In Vivo Toxicity Assays Completed.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

APRIL 14, 2022

Accordingly, state pesticide programs have tried to provide some clarity to fill the gap left by EPA. Similar issues arise under state and federal employee safety and worker Right-to-Know laws, as employees must be educated on the chemicals present and proper handling and risk management procedures. million cars on the road.

Environment 52

Environment Agriculture Compliance Compliance 52

Cannabis Law Report

APRIL 5, 2022

April 05, 2022 (GLOBE NEWSWIRE) — Metrc, the most trusted and experienced provider of cannabis regulatory systems in the U.S., Metrc will help facilitate Mississippi’s medical cannabis program’s data collection and regulatory oversight through its robust track-and-trace platform. LAKELAND, Fla.,

Safety 52

Safety Patients Dispensary Compliance 52

Veriheal

AUGUST 31, 2022

Harocopos and his team explain that OPCs, also known as supervised/safe consumption sites, are considered to be “health care facilities that aim to improve individual and community health, increase public safety and reduce the consequences of drug use, including overdose deaths, public drug use and syringe litter.” The Research Letter.

Consumption 104

Consumption Data Treatment Collective 104

Cannabis Law Report

JANUARY 24, 2022

Company is on track to announce interim data in mid-2022 from its Phase 2 clinical trial for lead kidney precision medicine product candidate GFB-887. Dr. Tucker has successfully advanced several programs through clinical development and regulatory approval. CAMBRIDGE, Mass.–(BUSINESS Dr. Tucker. “I

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

Cannabis Law Report

JULY 13, 2022

The 2022-23 budget and accompanying tax reform bill will provide significant and immediate relief to cannabis businesses, support equity operators, strengthen enforcement tools against illegal cannabis operators, and protect youth, environmental, and public safety programs funding. Supporting equity. million dollars to-date.

Compliance 52

Compliance Compliance Supply Chain Environment 52

SpeedWeed

JULY 29, 2021

Therefore, it is beneficial to create a program in the office of economic development to address these concerns and achieve these benefits.” The SB 21-111 states that a report must be submitted to the Governor between July 1, 2022 and July 1, 2023 with details about how the CBO spends its funds. View original article.

Data 52

Data Collective Business Cannabis 52

Cannabis Law Report

DECEMBER 2, 2021

These recommendations will be sent to the Oregon Health Authority (OHA) for consideration during formal rulemaking, with hearings scheduled from February 14 to February 25, 2022. Applicants must also authorize their training program to conduct a criminal background check. Core Psilocybin Facilitation Skills (16 Hours).

Law 52

Law Programs Therapy Education 52

Cannabis Law Report

MAY 29, 2022

To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision. 12] DEA, Drug Scheduling, [link] (last visited May 13, 2022). [13] 1, 2022), [link]. [14]

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Freedom Leaf

OCTOBER 15, 2018

Frontier Data predicts total sales of all CBD products in the U.S. billion by 2022. On July 23, the World Health Organization’s Expert Committee on Drug Dependence stated that “no public health problems have been associated with CBD use” and that “CBD has been found to be generally well tolerated with a good safety profile.”

DEA 51

DEA CBD Pharmaceutical Epilepsy 51

Cannabis Law Report

AUGUST 17, 2021

(Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

SEPTEMBER 12, 2022

08, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), is pleased to announce that it has completed what it believes to be the largest legal natural psilocybin harvest in Canadian history. VANCOUVER, British Columbia, Sept. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52

Cannabis Law Report

JANUARY 9, 2022

Since 2014 when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. Colorado has a robust medical program, with about 1.6% Legalizing cannabis for adults has been a wise investment. of the population enrolled.

Collective 52

Collective Policy Retail Programs 52

Cannabis Law Report

JUNE 1, 2021

Remains on track to achieve positive Adjusted EBITDA during the second half of FY 2022. opportunities in Fiscal 2022.” ecosystem strategy continues to gain traction with focus to further capitalize on growth opportunities in the U.S. Fourth Quarter Fiscal 2021 Financial Summary. (in in millions of Canadian dollars, unaudited).

Data 95

Data Vaping Supply Chain Business 95

Cannabis Law Report

DECEMBER 16, 2021

Because recreational use of marijuana is increasing, especially as more states legalize it, the CDC believes it’s important for all workplaces to implement and address marijuana policies in their motor vehicle safety programs. This program gives New Mexico an edge in the growth of cannabis infrastructure.

Cannabinoids 52

Cannabinoids Retail Policy Cultivation 52

Cannabis Law Report

AUGUST 27, 2021

The Rules will be effective until at least August 19, 2022. The Rules aim to promote social equity, safety and easy access to the cannabis marketplace while keeping local municipalities in control of how they want cannabis businesses to operate in their jurisdiction. –> Scroll to see full table data. Submission Fee.

Cultivation 105

Cultivation Conditions Business Cannabis 105

Cannabis Law Report

NOVEMBER 4, 2021

Education programming included the keynote presentation “Brand the Moment – establish a culture where everyone matters” featuring a conversation with Executive Coach & Author Simon T. Guided by Informa AllSecure , our team put health and safety at the top of our list of priorities in order to make this happen. About Fi Global.

Food 40

Food Events Supply Chain Business 40

Cannabis Law Report

AUGUST 4, 2021

We thus provide comparison with the pre-pandemic period of H1 2019 as an additional data point. At the time of FY 2020 results publication, we estimated that EUR 250m revenues had been lost in FY 2020 due to the impact of COVID-19 lockdowns and travel restrictions and the objective was to recover these revenues by 2022.

Business 105

Business Research and Development Environment Food 105

Cannabis Law Report

AUGUST 6, 2021

Adjusted EBITDA loss in Q1 2022 was $64 million , a $29 million narrower loss versus Q1 2021 driven by higher sales and lower operating expenses. Adjusted EBITDA loss in Q1 2022 was negatively impacted by a $10.1 First Quarter Fiscal 2022 Financial Summary. (in Highlights. in millions of Canadian. dollars, unaudited).

Vaping 105

Vaping Research and Development Data Business 105

SpeedWeed

FEBRUARY 19, 2021

We’re going to skip the data highlights today and dive right into our very special interview. And the great news on that is that we continue to work with new states, whether it’s a really big state like California or a smaller program like we have in Louisiana. Amanda Guerrero: Hey, Ed. Ed Keating: Yeah. So that’s the hemp side of it.

Seed-To-Sale 52

Seed-To-Sale Environment Supply Chain Data 52

Cannabis Law Report

MAY 26, 2022

was published in the Journal of Safety Research and made available online on May 18. Journal of Safety Research. Available online 18 May 2022. All data collection was completed prior to the COVID-19 pandemic. The two data collection teams were able to collect data at 47 of the 50 retail outlets.

Dispensary 52

Dispensary Research and Development Safety Recreational 52

Cannabis Law Report

JUNE 7, 2021

Since 2014, when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. Colorado has a robust medical program, with about 1.6% As of May 2021, states reported a combined total of $7.9 of the population enrolled.

Marijuana 91

Marijuana Retail Collective Programs 91

Peninsula Alternative Health

JUNE 12, 2023

This landmark legislation, which was developed in response to the approval of Question 4 on the 2022 ballot, brings about significant changes to the cannabis industry in the state. This agency will build upon the existing medical cannabis program regulations and ensure health, safety, and security within the industry.

Legislation 52

Legislation Packaging Edibles Concentrates 52

Peninsula Alternative Health

JUNE 12, 2023

This landmark legislation, which was developed in response to the approval of Question 4 on the 2022 ballot, brings about significant changes to the cannabis industry in the state. This agency will build upon the existing medical cannabis program regulations and ensure health, safety, and security within the industry.

Legislation 52

Legislation Packaging Edibles Concentrates 52

Cannabis Law Report

MAY 1, 2022

The potential for OHA to deny or delay approval to entheogenic practitioners who apply for training program approval because they lack access to a licensed service center to satisfy the required practicum. Join Chacruna’s Studies in Psychedelic Justice Studies. OHA’s Authority to Regulate for Religious/Spiritual Use.

Safety 52

Safety History Programs Clinical Trials 52

Cannabis Law Report

DECEMBER 20, 2021

First Patient Expected to be Enrolled by Q2 of 2022. Data To Support Regulatory Filings in the United States. The study will take place in Canada with a CTA filing and enrollment of the first patient anticipated by Q2 of 2022. BERWYN, Pa.–(BUSINESS

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

DECEMBER 16, 2021

One of our core goals for 2022 is to expand the number of licensed producers that use our scientific consumer experience data to help them drive stronger product revenues, and Jay brings unparalleled experience in building those kinds of relationships.”. What does this mean for the cannabis industry? About Zentrela.

Research and Development 52

Research and Development Data Retail Business 52

Cannabis Law Report

NOVEMBER 5, 2021

Under the ETS, large employers (100+ employees) have until January 4, 2022, to ensure that their workforce is fully vaccinated or require any workers who remain unvaccinated to produce a negative test result on at least a weekly basis before coming to work. Vaccinated participants in the safeCircle program are given a ‘blue pass.’

Compliance 52

Compliance Compliance Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 26, 2021

Topline results are expected in Q1 2022. With the anticipated launch of Pfizer’s oral COVID-19 antiviral drug candidate, Can-Fite has made a strategic decision to end its COVID-19 program and to focus its resources on its other clinical programs, all in advanced clinical trials. Fortified Balance Sheet. Financial Results.

Clinical Trials 52

Clinical Trials Research and Development Treatment Data 52

The Cannigma

FEBRUARY 1, 2023

Unlike healthy cells, these abnormal cells don’t die as they are typically programmed to do, and instead begin to grow and divide uncontrollably, effectively circumventing the body’s normal checks and balances. Only recently (2022) have laws governing cannabis research in the US become less restrictive.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

The Blunt Truth

JANUARY 15, 2021

Are there problems with Illinois’ social equity program? Last Friday, the Food and Drug Administration released a report on CBD, stating that more real-world data (RWD) is needed in order to evaluate the safety of the product. We’ve reported before on the problems with Illinois’ social equity program.

Research and Development 94

Research and Development CBD Programs Banking 94